*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Evocalcet is a selective calcimimetic agent developed for managing secondary hyperparathyroidism. Its core mechanism involves enhancing the sensitivity of calcium-sensing receptors on parathyroid glands to extracellular calcium, thereby suppressing parathyroid hormone secretion. The chemical structure corresponds to the molecular formula C<sub>21</sub>H<sub>25</sub>F<sub>4</sub>N<sub>3</sub>O<sub>2</sub>, with CAS number 850697-83-5.</p>
<h3>Application</h3>
<ul>
<li><strong>Dialysis Care:</strong> Administered orally to adult patients with chronic kidney disease on dialysis to control elevated parathyroid hormone levels.</li>
<li><strong>Endocrine Management:</strong> Used as an adjunct therapy in severe primary hyperparathyroidism where surgical intervention is not feasible.</li>
</ul>
<h3>Precautions</h3>
<p>Clinical use requires strict monitoring of serum calcium and phosphate levels to prevent hypocalcemia. Patients must avoid concomitant administration with strong CYP3A4 inhibitors. Storage should occur below 25°C in a dry environment, protected from light.</p>